{"id":2657,"date":"2018-05-22T23:19:05","date_gmt":"2018-05-22T17:49:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2657"},"modified":"2024-09-17T16:18:59","modified_gmt":"2024-09-17T10:48:59","slug":"notizia-latest-pharma-news-5","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5","title":{"rendered":"Celiac vaccine trial; New discovery in Nicotine; Nabriva lines up FDA filing; Rare Disease drug development accelerating"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial<\/strong><\/p>\n<p style=\"text-align: justify;\">ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical operations, as well as a new finance director. Company is looking forward to the advancement in development of its treatments for celiac disease and Type 1 diabetes.<\/p>\n<p style=\"text-align: justify;\"><strong>Nicotine found to be linked with obesity-fighting \u2018beige\u2019 fat in a new discovery <\/strong><\/p>\n<p style=\"text-align: justify;\">Researchers from the University of Michigan and\u00a0American University believe that they have\u00a0uncovered\u00a0a signaling pathway that stimulates beige cells to burn energy. In the process they have discovered that nicotine contributes to this process. This finding gives a ground support to the claims of some smokers of losing weight due to the habit.<\/p>\n<p style=\"text-align: justify;\"><strong>Nabriva lines up FDA filing after antibiotic clears second pivotal test<\/strong><\/p>\n<p style=\"text-align: justify;\">Nabriva Therapeutics\u2019 lefamulin\u00a0hits\u00a0the primary endpoint in second phase 3 trial. The positive results further boosts the prospects of the antibiotic, which is scheduled to go before the FDA later this year. In the second trial the drug was compared against already approved moxifloxacin antibiotic in patients with moderate community-acquired bacterial pneumonia (CABP). The trials showed identical outcomes with 90.8% clinical response rate.<\/p>\n<p style=\"text-align: justify;\"><strong>Rare Disease drug development timelines are accelerating <\/strong><\/p>\n<p style=\"text-align: justify;\">Currently, there are around 7,000 known rare diseases and disorders globally and still adding year after year. A single orphan disease may not be affecting lot of people but the global impact is significant. In the US alone, 25-35 million people are estimated to be suffering with a rare disease and around 50-66 percent of known rare diseases affect children. As per the normal timeline a drug takes around 10 years to get the approval and start marketing. Some rare disease are highly aggressive in nature and the patient cannot wait for such a long time to wait for the drug.<\/p>\n<p style=\"text-align: justify;\"><strong>\u00a0<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmusanT upgrading the management ahead of phase 2 celiac vaccine trial ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, M.D., as its new chief medical officer. The management is also boosted with new VPs in program management and clinical operations, as well as a new finance [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1155,204,1642,349,1641,1644,1643,1261,639,502],"industry":[17225],"therapeutic_areas":[17240,17227,17234],"class_list":["post-2657","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-consultancy","tag-delveinsight","tag-immusant","tag-latest-pharma-news","tag-latest-pharmaceutical-industry-news","tag-nabriva","tag-nicotine","tag-pharma-consulting","tag-pharma-news","tag-rare-disease","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | ImmusanT and Nabriva<\/title>\n<meta name=\"description\" content=\"ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, as its new CMO\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | ImmusanT and Nabriva\" \/>\n<meta property=\"og:description\" content=\"ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, as its new CMO\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-22T17:49:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-17T10:48:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | ImmusanT and Nabriva","description":"ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, as its new CMO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5","og_locale":"en_US","og_type":"article","og_title":"Pharma News | ImmusanT and Nabriva","og_description":"ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, as its new CMO","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-05-22T17:49:05+00:00","article_modified_time":"2024-09-17T10:48:59+00:00","og_image":[{"width":750,"height":315,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5","url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5","name":"Pharma News | ImmusanT and Nabriva","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","datePublished":"2018-05-22T17:49:05+00:00","dateModified":"2024-09-17T10:48:59+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"ImmusanT has upgraded its senior staff by appointing Daiichi Sankyo\u2019s SVP for internal medicine therapeutics, Ken Truitt, as its new CMO","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-5#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","width":750,"height":315,"caption":"Notizia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315-300x126.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ImmusanT<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">latest pharmaceutical industry news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nabriva<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nicotine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">ImmusanT<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">latest pharmaceutical industry news<\/span>","<span class=\"advgb-post-tax-term\">Nabriva<\/span>","<span class=\"advgb-post-tax-term\">Nicotine<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on May 22, 2018","modified":"Updated on Sep 17, 2024"},"absolute_dates_time":{"created":"Posted on May 22, 2018 11:19 pm","modified":"Updated on Sep 17, 2024 4:18 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2657"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2657\/revisions"}],"predecessor-version":[{"id":29556,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2657\/revisions\/29556"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2303"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2657"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2657"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}